Hyplafin (Finasteride)

Finasteride works by selectively inhibiting the type II 5‑alpha‑reductase enzyme. This blocks the conversion of testosterone into dihydrotestosterone (DHT), the androgen responsible for prostate enlargement and hair‑follicle miniaturisation. Lower DHT levels reduce androgen‑driven tissue growth and hair loss.

The exact dose of Hyplafin is determined by the prescribing clinician based on the patient’s condition, age, and response to therapy. Physicians may select a dose appropriate for benign prostatic hyperplasia or for male pattern hair loss, and the regimen is tailored to each individual.

Finasteride is classified as pregnancy category X, meaning it is contraindicated in women who are pregnant or may become pregnant because it can cause fetal harm. It is also not recommended for breastfeeding mothers, as it may be excreted in milk and affect a nursing infant.

To request Hyplafin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The most common alternative is dutasteride, another 5‑alpha‑reductase inhibitor that blocks both type I and type II isoforms. Dutasteride generally provides a greater reduction in DHT but may have a higher incidence of sexual side effects. Finasteride targets only type II, offering a well‑established safety profile for both BPH and hair‑loss indications.

Hyplafin should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack or container, protect them from moisture, heat and direct sunlight, and keep out of reach of children.

Hyplafin is taken orally, usually as a tablet swallowed whole with a glass of water. It can be taken with or without food, but consistency with respect to meals helps maintain stable drug levels. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious adverse events, although rare, include allergic reactions such as rash, swelling or anaphylaxis, the development of male breast cancer, and the possible emergence of high‑grade prostate cancer. Any sudden breast changes, severe skin reactions, or new urinary symptoms should prompt immediate medical evaluation.

Hyplafin is contraindicated in women, especially those who are pregnant or may become pregnant, and in children. Men with known hypersensitivity to finasteride or any component of the tablet should also avoid the product. Patients with liver disease should use it only under medical supervision.